@article{511aa34433cd481b80d1fa90a585b53d,
title = "Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study",
abstract = "We aimed to assess the safety and efficacy of lobeglitazone in patients with type 2 diabetes over 52 weeks through 28-week extension study. Clinical benefits in terms of glycemic and lipid control were maintained for 52 weeks. Lobeglitazone showed a favorable balance of efficacy and safety during the extension study.",
keywords = "Clinical trial, Lobeglitazone, Randomised trial, Thiazolidinediones",
author = "Kim, {Sun Hwa} and Kim, {Sin Gon} and Kim, {Doo Man} and Woo, {Jeong Taek} and Jang, {Hak Chul} and Chung, {Choon Hee} and Ko, {Kyung Soo} and Park, {Jeong Hyun} and Park, {Yong Soo} and Kim, {Sang Jin} and Choi, {Dong Seop}",
note = "Funding Information: This study was supported by the Medicine and Bio Project for {\textquoteleft}Development of New Medicine and Medical Material{\textquoteright} (Project No. 70007613, entitled {\textquoteleft}Clinical development of lobeglitazone, a thiazolidinedione insulin-sensitizing agent for diabetes mellitus{\textquoteright}) of the Chungcheong Leading Industry Office of the Korea Ministry of Knowledge Economy, which is a government organization. SGK's contribution was supported by a grant of the Korean Health Technology R&D Project (HI14C1731), Ministry of Health & Welfare, Republic of Korea. The research foundations had no role in the study design, data collection and analysis, decision to publish, or manuscript preparation. Publisher Copyright: {\textcopyright} 2015 Elsevier Ireland Ltd.",
year = "2015",
month = dec,
day = "1",
doi = "10.1016/j.diabres.2015.09.009",
language = "English",
volume = "110",
pages = "e27--e30",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "3",
}
